New agents for managing hyponatremia in hospitalized patients

American Journal of Health-System Pharmacy

Volumn 64, Issue 3, 2007, Pages 253-265

  Munger, Mark A ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Antimanic agents; Arginine vasopressin receptor antagonists; Conivaptan; Demeclocycline; Diuretics; Electrolytes; Hospitals; Hyponatremia; Lithium carbonate; Lixivaptan; Mechanism of action; Sodium chloride; Tetracyclines; Tolvaptan; Toxicity; Urea

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ARGIPRESSIN; ARGIPRESSIN RECEPTOR; CARBAMAZEPINE; CLARITHROMYCIN; CONIVAPTAN; DEMECLOCYCLINE; DESMOPRESSIN; DIGOXIN; ESOMEPRAZOLE; ETIRACETAM; FUROSEMIDE; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LITHIUM CARBONATE; LIXIVAPTAN; OXCARBAZEPINE; PROTON PUMP INHIBITOR; RITONAVIR; SODIUM; SODIUM CHLORIDE; TOLVAPTAN; UREA;

AMBULATORY CARE; BRADYCARDIA; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COMA; CREATININE BLOOD LEVEL; DEATH; DIURESIS; DIZZINESS; GASTROINTESTINAL HEMORRHAGE; HALLUCINATION; HEART FAILURE; HOSPITAL PATIENT; HUMAN; HYPONATREMIA; HYPOTENSION; INJECTION SITE INFLAMMATION; INJECTION SITE REACTION; INJURY; LETHARGY; LIVER CIRRHOSIS; NAUSEA; NEUROENDOCRINE DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESPIRATION DEPRESSION; REVIEW; RISK FACTOR; SEIZURE; SIDE EFFECT; SODIUM BLOOD LEVEL; SYMPTOMATOLOGY; THIRST; URINARY FREQUENCY; WATER RETENTION; WEAKNESS; XEROSTOMIA;

EID: 33846697650     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/060101     Document Type: Review

References (113)

1. Hawkins RC. Age and gender as risk factors for hyponatremia and hypernatremia. Clin Chim Acta. 2003; 337:169-72.
2. Androgue HJ, Madias NE. Hyponatremia. N Engl J Med. 2000; 342:1581-9.
3. Anderson RJ. Hospital-associated hyponatremia. Kidney Int. 1986; 29:1237-47.
4. Arieff AI. Hyponatremia, convulsions, respiratory arrest, and permanent brain damage after elective surgery in healthy women. N Engl J Med. 1986; 314:1529-35.
5. Verbalis JG. Hyponatremia: epidemiology, pathophysiology, and therapy. Curr Opin Nephrol Hypertens. 1993; 2:636-52.
6. Wong LL, Verbalis JG. Systemic diseases associated with disorders of water homeostasis. Endocrinol Metab Clin North Am. 2002; 31:121-40.
7. Beers MH, Berkow R. Normal laboratory values. In: Beers MH, Berkow R, eds. The Merck manual of diagnosis and therapy. 17th ed. Whitehouse Station, NJ: Merck and Co.; 1999:table 296-1.
8. Weiss-Guillet EM, Takala J, Jakob SM. Diagnosis and management of electrolyte emergencies. Best Pract Res Clin Endocrinol Metab. 2003; 17:623-51.
9. Verbalis JG. Disorders of body water homeostasis. Best Pract Res Clin Endocrinol Metab. 2003; 17:471-503.
10. Arieff AI. Osmotic failure: physiology and strategies for treatment. Hosp Pract. 1988; 23:173-4,187.
11. Freda BJ, Davidson MB, Hall PM. Evaluation of hyponatremia: a little physiology goes a long way. Cleve Clin J Med. 2004; 71:639-50.
12. Klein L, O'Connor CM, Leimberger JD et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure. Circulation. 2005; 111:2454-60.
13. Gheorghiade M, Adams K, O'Connor C et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF). Presented at 54th Annual American College of Cardiology Annual Scientific Session. Orlando, FL; 2005 Mar.
14. Gheorghiade M, Hellkamp AS, Pina IL et al. Hemodynamic characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial. Presented at 54th Annual American College of Cardiology Annual Scientific Session. Orlando, FL; 2005 Mar.
15. Oren RM. Hyponatremia in congestive heart failure. Am J Cardiol. 2005; 95(suppl):2B-7B.
16. Berl T, Verbalis J. Pathophysiology of water metabolism. In: Brenner BM, Rector FC, eds. Brenner & Rector's the kidney. 7th ed. Philadelphia: W. B. Saunders; 2004:857-919.
17. Nielsen S. Renal aquaporins: an overview. BJU Int. 2002; 90(suppl 3):1-6.
18. Nielsen S, Kwon TH, Christensen BM et al. Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol. 1999; 10:647-63.
19. Costello-Boerrigter LC, Boerrigter G, Burnett JC Jr. Revisiting salt and water retention: new diuretics, aquaretics, and natriuretics. Med Clin North Am. 2003; 87:475-91.
20. Knoers NV. Hyperactive vasopressin receptors and disturbed water homeostasis. N Engl J Med. 2005; 352:1847-50.
21. Ferguson JW, Therapondos G, Newby DE et al. Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis. Clin Sci. 2003; 105:1-8.
22. Schild L. The epithelial sodium channel: from molecule to disease. Rev Physiol Biochem Pharmacol. 2004; 151:93-107.
23. 2 receptor antagonists. Cardiovasc Res. 2001; 51:391-402.
24. Nakamura Y, Haneda T, Osaki J et al. Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin VIA receptor. Eur J Pharmacol. 2000; 391:39-48.
25. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol. 2005; 46:1785-91.
26. Thibonnier M, Conarty DM, Preston JA et al. Molecular pharmacology of human vasopressin receptors. Adv Exp Med Biol. 1998; 449:251-76.
27. Vaprisol (conivaptan hydrochloride injection) prescribing information. Deerfield, IL: Astellas Pharma; 2006.
28. Boh LE, ed. Pharmacy practice manual: a guide to clinical experience. 2nd ed. Baltimore: Lippincott Williams and Wilkins; 2001.
29. Schrier RW, Berl T. The patient with hyponatremia or hypernatremia. In: Schrier RW, ed. Manual of nephrology. 5th ed. Philadelphia: Lippincott Williams and Wilkins; 2000:21-36.
30. Sarvazyan A, Tatarinov A, Sarvazyan N. Ultrasonic assessment of tissue hydration status. Ultrasonics. 2005; 43:661-71.
31. Chung HM, Kluge R, Schrier RW et al. Clinical assessment of extracellular fluid volume in hyponatremia. Am J Med. 1987; 83:905-8.
32. Crook MA, Velauthar U, Moran L et al. Review of investigation and management of severe hyponatraemia in a hospital population. Ann Clin Biochem. 1999; 36(pt. 2):158-62.
33. Allison SP, Lobo DN. Fluid and electrolytes in the elderly. Curr Opin Clin Nutr Metab Care. 2004; 7:27-33.
34. Chatterjee K. Neurohormonal activation in congestive heart failure and the role of vasopressin. Am J Cardiol. 2005; 95(suppl):8B-13B.
35. Goldsmith SR. Congestive heart failure: potential role of arginine vasopressin antagonists in the therapy of heart failure. Congest Heart Fail. 2002; 8:251-6.
36. Borroni G, Maggi A, Sangiovanni A et al. Clinical relevance of hyponatraemia for the hospital outcome of cirrhotic patients. Dig Liver Dis. 2000; 32:605-10.
37. DeVita MV, Gardenswartz MH, Konecky A et al. Incidence and etiology of hyponatremia in an intensive care unit. Clin Nephrol. 1990; 34:163-6.
38. Lee CT, Guo HR, Chen JB. Hyponatremia in the emergency department. Am J Emerg Med. 2000; 18:264-8.
39. Coenraad MJ, Meinders AE, Vandenbroucke JP et al. Causes of hyponatremia in the departments of internal medicine and neurosurgery. Eur J Intern Med. 2003; 14:302-9.
40. Rabinstein AA, Wijdicks EF. Hyponatremia in critically ill neurological patients. Neurologist. 2003; 9:290-300.
41. Beigel R, Shiff E, Luckman J et al. Hyponatremia as a presenting sign of a pituitary intrasellar cyst. Isr Med Assoc J. 2005; 7:126-7.
42. Cole CD, Gottfried ON, Liu JK et al. Hyponatremia in the neurosurgical patient: diagnosis and management. Neurosurg Focus. 2004; 16:E9.
43. Wei T, Zuyuan R, Changbao S et al. Hyponatremia after transsphenoidal surgery of pituitary adenoma. Chin Med Sci J. 2003; 18:120-3.
44. Olson BR, Rubino D, Gumowski J et al. Isolated hyponatremia after transsphenoidal pituitary surgery. J Clin Endocrinol Metab. 1995; 80:85-91.
45. Casulari LA, Costa KN, Albuquerque RC et al. Differential diagnosis and treatment of hyponatremia following pituitary surgery. J Neurosurg Sci. 2003; 47:11-8.
46. Dickerson RN. Hyponatremia in neurosurgical patients: syndrome of inappropriate antidiuretic hormone or cerebral salt wasting syndrome. Hosp Pharm. 2002; 37:1336-42.
47. Chung HM, Kluge R, Schrier RW et al. Postoperative hyponatremia. A prospective study. Arch Intern Med. 1986; 146:333-6.
48. Miller M. Syndromes of excess antidiuretic hormone release. Crit Care Clin. 2001; 17:11-23.
49. Issa MM, Young MR, Bullock AR et al. Dilutional hyponatremia of TURP syndrome: a historical event in the 21st century. Urology. 2004; 64:298-301.
50. Ayus JC, Wheeler JM, Arieff AI. Postoperative hyponatremic encephalopathy in menstruant women. Ann Intern Med. 1992; 117:891-7.
51. Frizelle FA, Colls BM. Hyponatremia and seizures after bowel preparation: report of three cases. Dis Colon Rectum. 2005; 48:393-6.
52. Baajafer FS, Hammami MM, Mohamed GE. Prevalence and severity of hyponatremia and hypercreatininemia in short-term uncomplicated hypothyroidism. J Endocrinol Invest. 1999; 22:35-9.
53. Nakano M, Higa M, Ishikawa R et al. Hyponatremia with increased plasma antidiuretic hormone in a case of hypothyroidism. Intern Med. 2000; 39:1075-8.
54. Kamoi K, Tamura T, Tanaka K et al. Hyponatremia and osmoregulation of thirst and vasopressin secretion in patients with adrenal insufficiency. J Clin Endocrinol Metab. 1993; 77:1584-8.
55. Tang WW, Kaptein EM, Feinstein EI et al. Hyponatremia in hospitalized patients with the acquired immunodeficiency syndrome (AIDS) and the AIDS-related complex. Am J Med. 1993; 94:169-74.
56. Sridhar CB, Isaac BC. Hyponatremia in HIV infected patient. J Assoc Physicians India. 2005; 46:980-3.
57. Berghmans T, Paesmans M, Body JJ. A prospective study on hyponatremia in medical cancer patients: epidemiology, aetiology and differential diagnosis. Supp Care Cancer. 2000; 8:192-7.
58. Greenberg A. Diuretic complications. Am J Med Sci. 2000; 319:10-24.
59. Chow KM, Szeto CC, Wong TY et al. Risk factors for thiazide-induced hyponatraemia. QJM. 2003; 96:911-7.
60. Matsumoto H. Hyponatremia associated with selective serotonin reuptake inhibitors. Intern Med. 2005; 44:173-4.
61. Woo MH, Smythe MA. Association of SIADH with selective serotonin reuptake inhibitors. Ann Pharmacother. 1997; 3:108-10.
62. Fabian TJ, Amico JA, Kroboth PD et al. Paroxetine-induced hyponatremia in older adults. Arch Intern Med. 2004; 164:327-32.
63. Alderman CP. Syndrome of inappropriate antidiuretic hormone secretion secondary to venlafaxine. J Pharm Pract Res. 2002; 32:35-6.
64. Ertel GJ, Nesbit TW. Citalopram-related SIADH. J Pharm Technol. 2002; 19:91-3.
65. Movig KL, Leufkens HG, Lenderink AW et al. Serotonergic antidepressants associated with an increased risk for hyponatraemia in the elderly. Eur J Clin Pharmacol. 2002; 58:143-8.
66. Ryan M, Adams AG, Larive LL. Hyponatremia and leukopenia associated with oxcarbazepine following carbamazepine therapy. Am J Health-Syst Pharm. 2001; 58:1637-9.
67. Nasrallah K, Silver B. Hyponatremia associated with repeated use of levetiracetam. Epilepsia. 2005; 46:972-3.
68. Finch CK, Andrus MR, Curry WA. Nicotine replacement therapy-associated syndrome of inappropriate antidiuretic hormone. South Med J. 2004; 97:322-4.
69. Mennecier D, Ceppa F, Gidenne S et al. Hyponatremia with consciousness disturbance associated with esomeprazole. Ann Pharmacother. 2005; 39:774-5.
70. Callreus T, Ekman E, Andersen M. Hyponatremia in elderly patients treated with desmopressin for nocturia: a review of a case series. Eur J Clin Pharmacol. 2005; 61:281-4.
71. Rukskul P. Ecstasy (MDMA) ingestion related with severe hyponatremia in patients with mild head injury. J Med Assoc Thai. 2005; 88:41-4.
72. Patel GP, Kasiar JB. Syndrome of inappropriate antidiuretic hormone-induced hyponatremia associated with amiodarone. Pharmacotherapy. 2002; 22:649-51.
73. Ayus JC, Arieff AI. Pulmonary complications of hyponatremic encephalopathy. Noncardiogenic pulmonary edema and hypercapnic respiratory failure. Chest. 1995; 107:517-21.
74. Nzerue CM, Baffoe-Bonnie H, You W et al. Predictors of outcome in hospitalized patients with severe hyponatremia. J Natl Med Assoc. 2003; 95:335-43.
75. Ke C, Poon WS, Ng HK et al. The impact of acute hyponatraemia on severe traumatic brain injury in rats. Acta Neurochir Suppl. 2000; 76:405-8.
76. Ayus JC, Arieff AI. Chronic hyponatremic encephalopathy in postmenopausal women: association of therapies with morbidity and mortality. JAMA. 1999; 281:2299-304.
77. Laureno R, Karp BI. Myelinolysis after correction of hyponatremia. Ann Intern Med. 1997; 126:57-62.
78. Norenberg MD, Leslie KO, Robertson AS. Association between rise in serum sodium and central pontine myelinolysis. Ann Neurol. 1982; 11:128-35.
79. Sterns RH, Cappuccio JD, Silver SM et al. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J Am Soc Nephrol. 1994; 4:1522-30.
80. Sterns RH, Riggs JE, Schochet SS Jr. Osmotic demyelination syndrome following correction of hyponatremia. N Engl J Med. 1986; 314:1535-42.
81. Tareen N, Martins D, Nagami G et al. Sodium disorders in the elderly. J Natl Med Assoc. 2005; 97:217-24.
82. Sharabi Y, Illan R, Kamari Y et al. Diuretic induced hyponatraemia in elderly hypertensive women. J Hum Hypertens. 2002; 16:631-5.
83. Goh KP. Management of hyponatremia. Am Fam Physician. 2004; 69:2387-94.
84. Kraft MD, Btaiche IF, Sacks GS et al. Treatment of electrolyte disorders in adult patients in the intensive care unit. Am J Health-Syst Pharm. 2005; 62:1663-82.
85. Adrogué HJ. Consequences of inadequate management of hyponatremia. Am J Nephrol. 2005; 25:240-9.
86. Nguyen MK, Kurtz I. An analysis of current quantitative approaches to the treatment of severe symptomatic SIADH with intravenous saline therapy. Clin Exp Nephrol. 2005; 9:1-4.
87. Miller PD, Linas SL, Schrier RW. Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients. JAMA. 1980; 243:2513-5.
88. Schrier RW, Berl T, Anderson RJ. Osmotic and nonosmotic control of vasopressin release. Am J Physiol. 1979; 236: F321-32.
89. Goldsmith SR. Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure. Am J Cardiol. 2005; 95(9A):14B-23B.
90. Schrier RW, Lehman D, Zacherle B et al. Effect of furosemide on free water excretion in edematous patients with hyponatremia. Kidney Int. 1973; 3:30-4.
91. Thurman JM, Halterman RK, Berl T. Therapy of dysnatremic disorders. In: Brady HR, Wilcox CS, eds. Therapy in nephrology and hypertension. 2nd ed. Philadelphia: W. B. Saunders; 2003:335-8.
92. Vachharajani TJ, Zaman F, Abreo KD. Hyponatremia in critically ill patients. J Intensive Care Med. 2003; 18:3-8.
93. Gheorghiade M, Zimmer C, Czerwiec F et al. Improvement in hyponatremia: insights from the acute and chronic therapeutic impact of a vasopressin antagonist in chronic heart failure. Eur J Heart Fail Suppl. 2005; 4:79.
94. Gheorghiade M, Orlandi C, Burnett JC Jr et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J Card Fail. 2005; 11:260-9.
95. Gheorghiade M, Konstam MA, Udelson JE et al. Vasopressin receptor blockade with tolvaptan in chronic heart failure: differential effects in normonatremic and hyponatremic patients. J Am Coll Cardiol. 2002; 39:171A. Abstract.
96. Gheorghiade M, Gattis WA, O'Connor CM et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004; 291:1963-71.
97. 2 vasopressin antagonists in hyponatremia. Cardiovasc Res. 2001; 51:403-8.
98. 2 antagonist in cirrhotic patients with ascites. Hepatology. 2002; 36:1197-205.
99. Gerbes AL, Gulberg V, Gines P et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology. 2003; 124: 933-9.
100. Burnier M, Fricker AF, Hayoz D et al. Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects. Eur J Clin Pharmacol. 1999; 55:633-7.
101. Tahara A, Tomura Y, Wada KI et al. Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther. 1997; 282:301-8.
102. 2 receptor antagonist, in dogs. Eur J Pharmacol. 1997; 321:225-30.
103. 2 antagonist, increased serum sodium 2 days and 4 or 5 days after administration in patients with hyponatremia. Poster presented at the Endocrine Society 87th Annual Meeting. San Diego, CA; 2005 Jun.
104. Verbalis JG, Bisaha JG, Smith N. Novel vasopressin V1a and V2 antagonist conivaptan increases serum sodium concentration and effective water clearance in hyponatremia. Presented at American Society of Nephrology Renal Week 2004. St. Louis, MO; 2004 Oct-Nov.
105. Verbalis JG, Bisaha JG, Smith N. Novel vasopressin V1A and V2 antagonist (conivaptan) increases serum sodium concentration and effective water clearance in patients with hyponatremia. J Card Fail. 2004; 10(suppl):S27.
106. CardioKine. Lixivaptan: stage of development. www.cardiokine.com/ lixivaptan_development.asp (accessed 2006 Jul 5).
107. Muralidharan G, Meng X, DeCleene SA et al. Pharmacokinetics and pharmacodynamics of a novel vasopressin receptor antagonist, VPA-985, in healthy subjects. Clin Pharmacol Ther. 1999; 65:189.
108. Wong F, Blei AT, Blendis LM et al. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology. 2003; 37:182-91.
109. Gheorghiade M, Teerlink JR, Mebazaa A. Pharmacology of new agents for acute heart failure syndrome. Am J Cardiol. 2005; 96(6 suppl 1):68-73.
110. 2- receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation. 2003; 107:2690-6.
111. Gheorghiade M, Gattis WA, Barbagelata A et al. Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. Am Heart J. 2003; 145:S51-4.
112. Mansur JM, Chamerlik SJ. New roles for pharmacy managers in patient-centered care. Am J Health-Syst Pharm. 1995; 2:54-8.
113. American Society of Health-System Pharmacists. 2004 ASHP Leadership Conference on Pharmacy Practice Management executive summary: improving patient care and medication safety. Am J Health-Syst Pharm. 2005; 62:1303-10.